Leading Chinese biotech firm Wuxi AppTec says US hurdles will not dim acquisition appetite

South China Morning Post

12/01/2018

Thomas T.H. Chou

Mergers + Acquisitions | China, Private Equity + Venture Capital | China, and Corporate

In The News

Despite the broadened scope of CFIUS to review transactions, Morrison & Foerster partner Thomas T.H. Chou advised in the South China Morning Post article “Leading Chinese biotech firm Wuxi AppTec says US hurdles will not dim acquisition appetite” that Chinese firms are still actively seeking to make deals with U.S. companies.

“U.S. biotech companies generally remain quite interested in partnering with Chinese companies because of the enormous market potential and the recognition that the Chinese are increasingly innovative. That is why the industry trade groups are trying to find ways to help address U.S. national security concerns without cutting off the U.S. from the innovations that are occurring in China,” he said.

Email Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

©1996-2018 Morrison & Foerster LLP. All rights reserved.